Regeneron PharmaceuticalsREGNEarnings & Financial Report
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
REGN Q4 2025 Key Financial Metrics
营收
$3.9B
毛利润
N/A
营业利润
$879.9M
净利润
$844.6M
毛利率
N/A
营业利润率
22.7%
净利率
21.7%
同比增长
2.5%
EPS
$7.78
资金流向
Regeneron Pharmaceuticals Q4 2025 Financial Summary
Regeneron Pharmaceuticals reported revenue of $3.9B for Q4 2025, with a net profit of $844.6M (21.7% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $3.9B |
|---|---|
| Net Profit | $844.6M |
| Gross Margin | N/A |
| Operating Margin | 22.7% |
| Report Period | Q4 2025 |
Regeneron Pharmaceuticals Annual Revenue by Year
Regeneron Pharmaceuticals annual revenue history includes year-by-year totals (for example, 2025 revenue was $14.3B).
| Year | Annual Revenue |
|---|---|
| 2025 | $14.3B |
| 2024 | $14.2B |
| 2023 | $13.1B |
| 2022 | $12.2B |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $3.15B | $3.55B | $3.72B | $3.79B | $3.03B | $3.68B | $3.75B | $3.88B |
| 同比增长 | -0.5% | 12.3% | 10.6% | 10.3% | -3.7% | 3.6% | 0.9% | 2.5% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $34.37B | $36.09B | $37.44B | $37.76B | $37.55B | $38.22B | $40.17B | $40.56B |
| 总负债 | $7.38B | $7.88B | $8.12B | $8.41B | $8.16B | $8.28B | $9.21B | $9.30B |
| 股东权益 | $26.99B | $28.21B | $29.33B | $29.35B | $29.39B | $29.94B | $30.96B | $31.26B |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $1.51B | $354.0M | $1.29B | $1.26B | $1.05B | $1.14B | $1.62B | $1.17B |
Other Health Care Companies
ABBV
AbbVie
营收
$15.8B
净利润
$186.0M
AMGN
Amgen
营收
$9.9B
净利润
$1.3B
BIIB
Biogen
营收
$2.3B
净利润
$-48.9M
GILD
Gilead Sciences
营收
$7.8B
净利润
$3.1B
INCY
Incyte
营收
$1.5B
净利润
$299.3M
MRNA
Moderna
营收
$1.0B
净利润
$-200.0M
VRTX
Vertex Pharmaceuticals
营收
$3.2B
净利润
$1.2B
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
A
Agilent Technologies
营收
$1.9B
净利润
$434.0M
ALGN
Align Technology
营收
$995.7M
净利润
$56.8M